Aclaris Therapeutics, Inc. (ACRS)
USD 1.16
(6.94%)
USD 1.16
(6.94%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -39.45 Million USD | 11.53% |
| 2022 | -44.59 Million USD | -67.29% |
| 2021 | -26.65 Million USD | 37.83% |
| 2020 | -42.87 Million USD | -21.46% |
| 2019 | -35.3 Million USD | -33.19% |
| 2018 | -26.5 Million USD | 87.3% |
| 2017 | -208.71 Million USD | -591.76% |
| 2016 | -30.17 Million USD | -206.27% |
| 2015 | -9.85 Million USD | 8.42% |
| 2014 | -10.75 Million USD | -12.19% |
| 2013 | -9.58 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -32.36 Million USD | 17.96% |
| 2024 Q2 | -20.01 Million USD | 38.15% |
| 2023 Q3 | -38.73 Million USD | -26.19% |
| 2023 Q4 | -39.45 Million USD | -1.86% |
| 2023 Q1 | -44.11 Million USD | 1.06% |
| 2023 Q2 | -30.69 Million USD | 30.43% |
| 2023 FY | -39.45 Million USD | 11.53% |
| 2022 Q1 | -35.62 Million USD | -33.65% |
| 2022 FY | -44.59 Million USD | -67.29% |
| 2022 Q4 | -44.59 Million USD | 26.76% |
| 2022 Q3 | -60.88 Million USD | 9.83% |
| 2022 Q2 | -67.52 Million USD | -89.53% |
| 2021 Q4 | -26.65 Million USD | 49.64% |
| 2021 Q1 | -23.95 Million USD | 44.14% |
| 2021 Q2 | -102.06 Million USD | -326.18% |
| 2021 FY | -26.65 Million USD | 37.83% |
| 2021 Q3 | -52.93 Million USD | 48.14% |
| 2020 Q4 | -42.87 Million USD | -244.68% |
| 2020 FY | -42.87 Million USD | -21.46% |
| 2020 Q3 | -12.43 Million USD | 41.88% |
| 2020 Q2 | -21.4 Million USD | 49.98% |
| 2020 Q1 | -42.79 Million USD | -21.23% |
| 2019 Q3 | 674 Thousand USD | 191.2% |
| 2019 Q2 | -739 Thousand USD | 78.33% |
| 2019 Q1 | -3.41 Million USD | 87.13% |
| 2019 FY | -35.3 Million USD | -33.19% |
| 2019 Q4 | -35.3 Million USD | -5337.39% |
| 2018 Q3 | -25.99 Million USD | 42.84% |
| 2018 Q2 | -45.48 Million USD | 16.91% |
| 2018 Q1 | -54.73 Million USD | 73.77% |
| 2018 FY | -26.5 Million USD | 87.3% |
| 2018 Q4 | -26.5 Million USD | -1.94% |
| 2017 FY | -208.71 Million USD | -591.76% |
| 2017 Q1 | -23.67 Million USD | 21.52% |
| 2017 Q4 | -208.71 Million USD | -247.53% |
| 2017 Q3 | -60.05 Million USD | -83.61% |
| 2017 Q2 | -32.7 Million USD | -38.14% |
| 2016 Q3 | -17.79 Million USD | 44.06% |
| 2016 Q4 | -30.17 Million USD | -69.54% |
| 2016 FY | -30.17 Million USD | -206.27% |
| 2016 Q2 | -31.81 Million USD | -142.29% |
| 2016 Q1 | -13.13 Million USD | -33.3% |
| 2015 Q2 | -9.85 Million USD | -161.08% |
| 2015 Q1 | 16.12 Million USD | 249.95% |
| 2015 Q3 | -25.41 Million USD | -157.98% |
| 2015 FY | -9.85 Million USD | 8.42% |
| 2015 Q4 | -9.85 Million USD | 61.25% |
| 2014 FY | -10.75 Million USD | -12.19% |
| 2014 Q4 | -10.75 Million USD | 0.0% |
| 2014 Q1 | 13.32 Million USD | 0.0% |
| 2013 FY | -9.58 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Applied DNA Sciences, Inc. | -5.91 Million USD | -567.091% |
| Aspira Women's Health Inc. | -331 Thousand USD | -11819.033% |
| Biodesix, Inc. | 34.3 Million USD | 214.997% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | -580.683% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -3074.11% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | -3074.11% |
| Bionano Genomics, Inc. | 34.88 Million USD | 213.101% |
| CareDx, Inc | -47.97 Million USD | 17.767% |
| Check-Cap Ltd. | -24.75 Million USD | -59.363% |
| Castle Biosciences, Inc. | -83.53 Million USD | 52.77% |
| DarioHealth Corp. | -7.54 Million USD | -422.682% |
| Exact Sciences Corporation | 1.94 Billion USD | 102.024% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 52.218% |
| Guardant Health, Inc. | 220.22 Million USD | 117.914% |
| ICON Public Limited Company | 3.56 Billion USD | 101.108% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 107.987% |
| Illumina, Inc. | 1.21 Billion USD | 103.25% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | -626.201% |
| iSpecimen Inc. | -2.14 Million USD | -1737.18% |
| Standard BioTools Inc. | 46.5 Million USD | 184.832% |
| MDxHealth SA | 18.88 Million USD | 308.907% |
| 23andMe Holding Co. | -141.37 Million USD | 72.093% |
| Medpace Holdings, Inc. | -103.32 Million USD | 61.818% |
| Myriad Genetics, Inc. | 88.1 Million USD | 144.781% |
| Mainz Biomed B.V. | 349.85 Thousand USD | 11376.672% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | -1517.214% |
| NeoGenomics, Inc. | 269.19 Million USD | 114.656% |
| Neogen Corporation | 735.62 Million USD | 105.363% |
| Inotiv, Inc. | 382.14 Million USD | 110.324% |
| Natera, Inc. | -200.1 Million USD | 80.284% |
| OpGen, Inc. | 11.89 Million USD | 431.756% |
| OPKO Health, Inc. | 230.68 Million USD | 117.102% |
| Psychemedics Corporation | 334 Thousand USD | 11911.976% |
| Prenetics Global Limited | -43.33 Million USD | 8.965% |
| Prenetics Global Limited | -43.33 Million USD | 8.965% |
| Precipio, Inc. | -386 Thousand USD | -10120.725% |
| Personalis, Inc. | -8.02 Million USD | -391.798% |
| RadNet, Inc. | 1.14 Billion USD | 103.435% |
| Sera Prognostics, Inc. | -2.02 Million USD | -1851.137% |
| Sotera Health Company | 2.02 Billion USD | 101.948% |
| Neuronetics, Inc. | 2.79 Million USD | 1510.511% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -157.234% |
| Star Equity Holdings, Inc. | -15.33 Million USD | -157.234% |
| Trinity Biotech plc | 63.73 Million USD | 161.899% |
| T2 Biosystems, Inc. | 33.8 Million USD | 216.691% |
| Twist Bioscience Corporation | -192.4 Million USD | 79.495% |
| Exagen Inc. | -12.77 Million USD | -208.894% |